Opsona Therapeutics is a leading drug development company specialising in the human immune system.

Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.

Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs. The company has research locations in Dublin (Ireland) and Lausanne (Switzerland). Find out more about Opsona

Our Products
Opsona Therapeutics is developing a number of highly innovative products to modulate the human immune system.

Our ability to deliver is reflected in our partnerships with global companies such as Wyeth and investors including Genentech & Novartis Venture Funds.

Discover more about Opsona’s products.

Innate immune system and adaptive immune system

Our Research

Our research is focused on using targeted approaches to explore the role of Toll-Like Receptors in innate immune pathways.

A large body of recent scientific research suggests that understanding TLRs & TLR signalling is the key to developing improved drugs for the treatment of autoimmune/inflammatory conditions, cancers and infectious diseases.

latest news

Opsona Therapeutics Appoints CFO & Senior Business Development Executive to Management Team
Appointment of new CFO & Senior Director Business Development

Opsona Appoints new Chairman & Non Executive Director
Dr Bernd Seizinger new Chairman for Opsona and Dr Gosse Bruinsma Non Executive Director

Opsona Therapeutics Founder Awarded Prestigious Boyle Medal
Opsona Founder Dr Luke O'Neill awarded prestigious Boyle Medal 2009 for groundbreaking dicsoveries in Innate Immunity, specifically Toll Like receptor (TLR) signalling